Korean J Urogenit Tract Infect Inflamm.  2013 Oct;8(2):83-89. 10.14777/kjutii.2013.8.2.83.

Urothelial Changes by Inflammation in Interstitial Cystitis/Painful Bladder Syndrome

• Choi H
• Bae JH

• KMID: 1502112
• DOI: http://doi.org/10.14777/kjutii.2013.8.2.83

Abstract

Bladder pain syndrome/interstitial cystitis (BPS/IC) is a chronic disease. Symptoms of IC are often exacerbated by bladder filling and are associated with various urinary symptoms. IC is diagnosed by exclusion steps for differentiation from other confusable diseases. The pathophysiology and etiology of BPS/IC is not completely understood. IC is generally assumed to involve changes in the bladder wall as well as alterations in both structural abnormality of pain processing and its modulation. Alterations of the bladder wall at the molecular and structural levels in urothelium along with their adjacent structures have been observed in human patients. Bladder nerves, urothelial cells, and smooth muscles are likely to play an important role through active communication with the immune and inflammatory systems. This review provides recent information on patients with PBS/IC and their abnormalities within the bladder.

Keyword

Intersititial cystitis; Urothelium; Inflammation

MeSH Terms

Chronic Disease
Cystitis
Humans
Inflammation*
Muscle, Smooth
Urinary Bladder*
Urothelium

Reference

1. Dell JR. Interstitial cystitis/painful bladder syndrome: appropriate diagnosis and management. J Womens Health (Larchmt). 2007; 16:1181–7.

2. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn. 2002; 21:167–78.

3. Hanno PM, Landis JR, Matthews-Cook Y, Kusek J, Nyberg L Jr. The diagnosis of interstitial cystitis revisited: lessons learned from the National Institutes of Health Interstitial Cystitis Database study. J Urol. 1999; 161:553–7.

4. van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008; 53:60–7.

5. Curhan GC, Speizer FE, Hunter DJ, Curhan SG, Stampfer MJ. Epidemiology of interstitial cystitis: a population based study. J Urol. 1999; 161:549–52.

6. Warren JW, Keay SK, Meyers D, Xu J. Concordance of interstitial cystitis in monozygotic and dizygotic twin pairs. Urology. 2001; 57(6 Suppl 1):22–5.

7. Kim YS, Longhurst PA, Wein AJ, Levin RM. Effects of sensitization on female guinea pig urinary bladder function: in vivo and in vitro studies. J Urol. 1991; 146:454–7.

8. Parsons CL, Lilly JD, Stein P. Epithelial dysfunction in nonbacterial cystitis (interstitial cystitis). J Urol. 1991; 145:732–5.

9. Lilly JD, Parsons CL. Bladder surface glycosaminoglycans is a human epithelial permeability barrier. Surg Gynecol Obstet. 1990; 171:493–6.

10. Holm-Bentzen M, Lose G. Pathology and pathogenesis of interstitial cystitis. Urology. 1987; 29(4 Suppl):8–13.

11. Oravisto KJ. Interstitial cystitis as an autoimmune disease. A review. Eur Urol. 1980; 6:10–3.

12. Leppilahti M, Tammela TL, Huhtala H, Kiilholma P, Leppilahti K, Auvinen A. Interstitial cystitis-like urinary symptoms among patients with Sjögren's syndrome: a population-based study in Finland. Am J Med. 2003; 115:62–5.

13. Hanno P, Levin RM, Monson FC, Teuscher C, Zhou ZZ, Ruggieri M, et al. Diagnosis of interstitial cystitis. J Urol. 1990; 143:278–81.

14. Silk MR. Bladder antibodies in interstitial cystitis. J Urol. 1970; 103:307–9.

15. Jokinen EJ, Alfthan OS, Oravisto KJ. Antitissue antibodies in interstitial cystitis. Clin Exp Immunol. 1972; 11:333–9.

16. Harrington DS, Fall M, Johansson SL. Interstitial cystitis: bladder mucosa lymphocyte immunophenotyping and peripheral blood flow cytometry analysis. J Urol. 1990; 144:868–71.

17. MacDermott JP, Miller CH, Levy N, Stone AR. Cellular immunity in interstitial cystitis. J Urol. 1991; 145:274–8.

18. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005; 2005:273–9.

19. Cai B, Chang SH, Becker EB, Bonni A, Xia Z. p38 MAP kinase mediates apoptosis through phosphorylation of BimEL at Ser-65. J Biol Chem. 2006; 281:25215–22.

20. Ambrosino C, Nebreda AR. Cell cycle regulation by p38 MAP kinases. Biol Cell. 2001; 93:47–51.

21. Bullock AD, Becich MJ, Klutke CG, Ratliff TL. Experimental autoimmune cystitis: a potential murine model for ulcerative interstitial cystitis. J Urol. 1992; 148:1951–6.

22. Sairanen J, Tammela TL, Leppilahti M, Multanen M, Paananen I, Lehtoranta K, et al. Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study. J Urol. 2005; 174:2235–8.

23. Ueda T, Tamaki M, Ogawa O, Yamauchi T, Yoshimura N. Improvement of interstitial cystitis symptoms and problems that developed during treatment with oral IPD-1151T. J Urol. 2000; 164:1917–20.

24. Bade JJ, Rijcken B, Mensink HJ. Interstitial cystitis in the Netherlands: prevalence, diagnostic criteria and therapeutic preferences. J Urol. 1995; 154:2035–7. discussion 2037-8.

25. Dundore PA, Schwartz AM, Semerjian H. Mast cell counts are not useful in the diagnosis of nonulcerative interstitial cystitis. J Urol. 1996; 155:885–7.

26. Larsen S, Thompson SA, Hald T, Barnard RJ, Gilpin CJ, Dixon JS, et al. Mast cells in interstitial cystitis. Br J Urol. 1982; 54:283–6.

27. Sant GR, Theoharides TC. The role of the mast cell in interstitial cystitis. Urol Clin North Am. 1994; 21:41–53.

28. Theoharides TC. Mast cells: the immune gate to the brain. Life Sci. 1990; 46:607–17.

29. Stead RH, Dixon MF, Bramwell NH, Riddell RH, Bienenstock J. Mast cells are closely apposed to nerves in the human gastrointestinal mucosa. Gastroenterology. 1989; 97:575–85.

30. Dimitriadou V, Buzzi MG, Moskowitz MA, Theoharides TC. Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells. Neuroscience. 1991; 44:97–112.

31. Aldenborg F, Fall M, Enerbäck L. Proliferation and transepithelial migration of mucosal mast cells in interstitial cystitis. Immunology. 1986; 58:411–6.

32. Bouchelouche K, Horn T, Nordling J, Larsen S, Hald T. The action of cysteinyl-leukotrienes on intracellular calcium mobilization in human detrusor myocytes. BJU Int. 2001; 87:690–6.

33. Pang X, Sant G, Theoharides TC. Altered expression of bladder mast cell growth factor receptor (c-kit) in interstitial cystitis. Urology. 1998; 51:939–44.

34. Feltis JT, Perez-Marrero R, Emerson LE. Increased mast cells of the bladder in suspected cases of interstitial cystitis: a possible disease marker. J Urol. 1987; 138:42–3.

35. Serel TA, Soyupek S, Candir O. Association between mast cells and bladder carcinoma. Urol Int. 2004; 72:299–302.

36. Letourneau R, Pang X, Sant GR, Theoharides TC. Intragranular activation of bladder mast cells and their association with nerve processes in interstitial cystitis. Br J Urol. 1996; 77:41–54.

37. Sant GR, Propert KJ, Hanno PM, Burks D, Culkin D, Diokno AC, et al. Interstitial Cystitis Clinical Trials Group. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol. 2003; 170:810–5.

38. Seshadri P, Emerson L, Morales A. Cimetidine in the treatment of interstitial cystitis. Urology. 1994; 44:614–6.

39. Elbadawi AE, Light JK. Distinctive ultrastructural pathology of nonulcerative interstitial cystitis: new observations and their potential significance in pathogenesis. Urol Int. 1996; 56:137–62.

40. Lowe EM, Anand P, Terenghi G, Williams-Chestnut RE, Sinicropi DV, Osborne JL. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol. 1997; 79:572–7.

41. Hohenfellner M, Nunes L, Schmidt RA, Lampel A, Thüroff JW, Tanagho EA. Interstitial cystitis: increased sympathetic innervation and related neuropeptide synthesis. J Urol. 1992; 147:587–91.

42. Bonini S, Lambiase A, Bonini S, Levi-Schaffer F, Aloe L. Nerve growth factor: an important molecule in allergic inflammation and tissue remodelling. Int Arch Allergy Immunol. 1999; 118:159–62.

43. Steers WD, Tuttle JB. Mechanisms of disease: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat Clin Pract Urol. 2006; 3:101–10.

44. Chai TC, Zhang CO, Shoenfelt JL, Johnson HW Jr, Warren JW, Keay S. Bladder stretch alters urinary heparin-binding epidermal growth factor and antiproliferative factor in patients with interstitial cystitis. J Urol. 2000; 163:1440–4.

45. Rosamilia A, Cann L, Scurry J, Rogers P, Dwyer P. Bladder microvasculature and the effects of hydrodistention in interstitial cystitis. Urology. 2001; 57(6 Suppl 1):132.

46. Wilkinson DR, Erickson AD. Urinary and serologic markers for interstitial cystitis: an update. Curr Urol Rep. 2006; 7:414–22.

47. Keay SK, Szekely Z, Conrads TP, Veenstra TD, Barchi JJ Jr, Zhang CO, et al. An antiproliferative factor from interstitial cystitis patients is a frizzled 8 protein-related sialoglycopeptide. Proc Natl Acad Sci U S A. 2004; 101:11803–8.

48. Nickel JC, Barkin J, Forrest J, Mosbaugh PG, Hernandez-Graulau J, Kaufman D, et al. Elmiron Study Group. Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis. Urology. 2005; 65:654–8.